Bayer: 5 key drugs to have combined peak sales of 5.5 billion euro

LEVERKUSEN, Germany Wed Nov 14, 2012 3:17pm IST

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011. REUTERS/Fabrizio Bensch

A man rides a bicycle in front of the building of Germany's largest drugmaker Bayer HealthCare Pharmaceuticals in Berlin April 28, 2011.

Credit: Reuters/Fabrizio Bensch

Related Topics

Stocks

   

LEVERKUSEN, Germany (Reuters) - Bayer said its five most promising new drugs have an annual peak sales potential of more than 5.5 billion euros ($7 billion).

The sales forecast comprises anti-clotting pill Xarelto, ophthalmic drug Eylea, also calle VEGF Trap-Eye, anti-cancer products Alpharadin and Stivarga, as well as lung treatment riociguat.

Last year, Bayer said four of the drugs, excluding riociguat, would have a peak sales potential of more than 5 billion euros.

(Reporting by Frank Siebelt; Writing by Ludwig Burger)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Bullying Impact

Reuters Showcase

A Little Help

A Little Help

Researchers "buzz" the brain to speed up learning.  Video 

Disease Outbreak

Disease Outbreak

WHO says West African Ebola outbreak to last 2-4 months.  Full Article 

Healthy Food

Healthy Food

For teen girls, fruits and veggies linked to lower risk of breast condition.  Full Article 

Milk Effect

Milk Effect

Drinking milk may slow women's knee arthritis.  Full Article 

Rising Obesity

Rising Obesity

U.S. childhood obesity rates have increased since 1999: study.  Full Article 

Quality Check

Quality Check

Just because it's sweet and sticky doesn't mean it's 'honey': FDA.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.   Full Coverage